Eli Lilly (NY:LLY)

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Is AbbVie Stock Outperforming the Nasdaq?

November 26, 2025

Companies and investors see AI as a game-changing technology.

Topics Stocks

Could AI Infrastructure Spending Be the Next Gold Rush for Investors? ↗

November 26, 2025

The weight loss drug market may approach almost $100 billion by the end of the decade.

Topics Artificial Intelligence

Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗

November 26, 2025

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

November 25, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Should You Buy the Massive Dip in Novo Nordisk Stock?

November 25, 2025

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Here's Why Novo Nordisk Stock Popped Today ↗

November 25, 2025

As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy...

The Great Divide: Is the Market Offering a Dip or Signalling a Bear?

November 25, 2025

Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Topics Artificial Intelligence Economy Stocks

Is UnitedHealth Group Stock Underperforming the Nasdaq?

November 25, 2025

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Topics Stocks

A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling ↗

November 25, 2025

Via MarketBeat

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

November 25, 2025

This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000? ↗

Topics ETFs

November 24, 2025

The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk ↗

Topics Government World Trade

November 24, 2025

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.

Via Benzinga

Topics ETFs

US Stock Market Navigates AI Euphoria and Rate Cut Hopes Amidst Mounting Volatility

November 24, 2025

The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless...

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...

Topics Artificial Intelligence Economy Electric Vehicles

Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint

November 24, 2025

Eli Lilly fell while Biogen jumped.

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps ↗

November 24, 2025

Via Investor's Business Daily

Eli Lilly & Co (NYSE:LLY) Presents a Compelling Case for Growth at a Reasonable Price ↗

November 24, 2025

Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability.

Via Chartmill

1 Spectacular Warren Buffett-Approved Index Fund That Could Turn $500 Per Month Into $1 Million ↗

November 24, 2025

Investing in an S&P 500 index fund can be a great way to build long-term wealth.

After a bruising week, Wall Street regained its footing on Friday as rate-cut hopes resurfaced and fears around the AI sell-off eased, if only slightly. Solid PMI data and improving inflation...

Topics ETFs Economy Stocks

Wall Street Rebounds—but Confidence Remains on a Short Leash ↗

November 24, 2025

Via Chartmill

Topics Artificial Intelligence Economy

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗

November 24, 2025

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Via Stocktwits

Q3 Earnings Outperformers: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Stocks

November 23, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Billionaire Stanley Druckenmiller Dropped Nvidia, Palantir, and Eli Lilly Over the Past Year and Just Bought the 2 Cheapest Magnificent Seven Stocks. ↗

November 23, 2025

These Magnificent Seven players are well-positioned to benefit in the AI boom.

Who says you have to choose between the two?

Topics Artificial Intelligence

2 Top Dividend Stocks for Growth-Oriented Investors ↗

November 23, 2025

Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗

Topics Artificial Intelligence

November 23, 2025

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗

Topics Government

November 22, 2025

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

November is a great month to be thankful for opportunities to invest in these fantastic companies.

3 Top Dividend Stocks to Buy in November ↗

November 22, 2025